EGFR and neoplasm: When patients were grouped according to generation of EGFR-TKIs, analyses showed generally similar trends to those observed in the overall population, i.e., shorter rwPFS and OS in patients with TP53 co-mutations than in patients with TP53 wild-type tumor (Supplementary Table S5).